Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells

International Journal of Urology

Volumn 13, Issue 5, 2006, Pages 593-600

  Asahi, Hideki ^a   Mizokami, Atsushi ^a,c   Miwa, Sotaro ^a   Keller, Evan T ^b   Koshida, Kiyoshi ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NONE   (Japan)

Author keywords

Bisphosphonate; Minodronate; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CASPASE 3; GELATINASE A; INCADRONIC ACID; MINODRONIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE RELATED PROTEIN; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; OSTEOCLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CYTOKINES; DIPHOSPHONATES; GENE EXPRESSION; GROWTH SUBSTANCES; HUMANS; INHIBITORY CONCENTRATION 50; MALE; OSTEOCLASTS; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33646816025     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01360.x     Document Type: Article

References (47)

1. Denis L. Prostate cancer. Primary hormonal treatment. Cancer 1993 71 3 Suppl. 1050 8.
2. Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 1998 160:1220 9.
3. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999 54 6A Suppl. 30 5.
4. Oh WK. Chemotherapy for patients with advanced prostate carcinoma: a new option for therapy. Cancer 2000 88 12 Suppl. 3015 21.
5. Jacobs SC. Spread of prostatic cancer to bone. Urology 1983 21:337 44.
6. Galasko CS. Skeletal metastases. Clin. Orthop. 1986 210:18 30.
7. Coleman RE. Skeletal complications of malignancy. Cancer 1997 80 8 Suppl. 1588 94.
8. Berruti A, Dogliotti L, Bitossi R et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. 2000 164:1248 53.
9. Hughes DE, Wright KR, Uy HL et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner Res. 1995 10:1478 87.
10. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner Res. 1998 13:581 9.
11. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharmacol. 1999 56:131 40.
12. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 1996 334:488 93.
13. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001 91:1191 200.
14. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 2000 82:1459 68.
15. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001 61:4418 24.
16. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 2001 84:1126 34.
17. Heidenreich A, Hofmann R, Engelmann UH. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J. Urol. 2001 165:136 40.
18. Asahi H, Mizokami A, Maeda Y, Komatsu K, Koshida K, Namiki M. Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis. J. Urol. 2003 169:281 2.
19. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994 369:321 3.
20. Reed JC. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 1994 124:1 6.
21. Tewari M, Quan LT, O'Rourke K et al. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly (ADP-ribose) polymerase. Cell 1995 81:801 9.
22. Nicholson DW, Ali A, Thornberry NA et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995 376:37 43.
23. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc) 2002 38:91 102.
24. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000 88 12 Suppl. 2979 88.
25. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001 61:2602 8.
26. Virtanen SS, Vaananen HK, Harkonen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002 62:2708 14.
27. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J. Urol. 2003 170:246 52.
28. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer 2001 84:951 8.
29. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 1998 95:3597 602.
30. Lum L, Wong BR, Josien R et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha) -converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J. Biol. Chem. 1999 274:13 13 18.
31. Zhang J, Dai J, Qi Y et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Invest. 2001 107:1235 44.
32. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997 89:309 19.
33. Brown JM, Corey E, Lee ZD et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology 2001 57:611 16.
34. Horwood NJ, Elliott J, Martin TJ, Gillespie MT. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 1998 139:4743 6.
35. Viereck V, Emons G, Lauck V et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. 2002 291:680 6.
36. Strewler GJ. The physiology of parathyroid hormone-related protein. N. Engl. J. Med. 2000 342:177 85.
37. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int. J. Cancer 1999 80:257 64.
38. Dougherty KM, Blomme EA, Koh AJ et al. Parathyroid hormone-related protein as a growth regulator of prostate carcinoma. Cancer Res. 1999 59:6015 22.
39. Kusano K, Miyaura C, Inada M et al. Regulation of matrix metalloproteinases (MMP-2-3-9, and - 13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998 139:1338 45.
40. Pajouh MS, Nagle RB, Breathnach R, Finch JS, Brawer MK, Bowden GT. Expression of metalloproteinase genes in human prostate cancer. J. Cancer Res. Clin. Oncol. 1991 117:144 50.
41. Hamdy FC, Fadlon EJ, Cottam D et al. Matrix metalloproteinase 9 expression in primary human prostatic adenocarcinoma and benign prostatic hyperplasia. Br. J. Cancer 1994 69:177 82.
42. Montironi R, Fabris G, Lucarini G, Biagini G. Location of 72-kd metalloproteinase (type IV collagenase) in untreated prostatic adenocarcinoma. Pathol. Res. Pract. 1995 191:1140 6.
43. Hashimoto K, Kihira Y, Matuo Y, Usui T. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate. J. Urol. 1998 160:1872 6.
44. Bodey B, Bodey B Siegel SE, Kaiser HE. Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer. In Vivo 2001 15:65 70.
45. Stearns ME, Wang M. Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin. Exp. Metastasis 1998 16:693 702.
46. Miwa S, Mizokami A, Keller ET et al. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Cancer Res. 2005 65:8818 25.
47. Cui N, Nomura T, Noma H et al. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Clin. Cancer Res. 2005 11:2713 19.